ArticleAsian Pacific journal of cancer prevention : APJCP2025
The Effectiveness and Adverse Events of Eribulin Monotherapy in Indonesian Metastatic Breast Cancer (MBC) Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMetastatic breast cancer (MBC) remains a major cause of cancer-related mortality, with limited treatment options in advanced stages. Eribulin is now recommended for MBC and covered by the Indonesian National Health Insurance Policy as monotherapy for 6 cycles. However, data on its effectiveness and safety in Indonesian patients remain scarce. This study aimed to evaluate the disease control rate, overall survival (OS), and adverse events of eribulin monotherapy after 6 treatment cycles in Indonesian MBC patients.
methodsThis multi-center bidirectional longitudinal study was conducted in Indonesia (November 2023 - December 2024). Patients with stage IV MBC receiving eribulin were included. Demographic data, tumor response, OS, and adverse events were extracted from medical records. Kaplan-Meier analysis and the log-rank test were used to assess OS, while Cox regression evaluated potential prognostic factors. Adverse events were analyzed using descriptive statistics.
resultA total of 53 patients were included, with 54.7% aged >50 years and 56.6% classified as luminal subtype. The majority (51.0%) received eribulin as a third-line or later treatment, and 56.6% had lung metastases. Disease control was achieved in 43.4% of patients after 6 cycles. The median OS was 10 months (95% CI: 6.81 - 13.18 months). Eribulin was well tolerated, with nausea (32.1%) being the most common adverse event.
conclusionThis study suggests that eribulin monotherapy is associated with disease control and survival benefits in Indonesian MBC patients while maintaining a manageable safety profile. However, further prospective studies are needed to confirm its long-term efficacy, impact beyond 6 cycles, and comparative effectiveness relative to other chemotherapy regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.